Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector.

Amgen has secured EC approval for Uplizna as an add-on treatment to standard therapy for adults with gMG who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.

Madrigal is eying an expansion of MASH blockbuster Rezdiffra’s capabilities via combination with precision siRNA gene ...

Every two years, South Korea adjusts the national health insurance (NHI) prices for existing listed products based on the ...

Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi, after the French vaccine specialist announced it would not renew existing CEO Paul Hudson’s contract.

Citius Oncology has signed an exclusive distribution agreement with Uniphar to enable access to Lymphir in selected western ...

THX Pharma and Biocodex have entered into a strategic licensing agreement to further the development of two drug candidates, ...

The FDA’s refusal to review Moderna's flu vaccine, mRNA-1010, comes within a wider push from the US government to alter ...

Insilico Medicine has announced several AI drug discovery collaborations with CMS across several projects in CNS and ...

MSD has received the US FDA approval for Keytruda and Keytruda Qlex along with paclitaxel, with or without bevacizumab, for ovarian cancer.

Despite the FDA’s CNPV scheme generating high interest, the process around how voucher awards are prioritised remains unclear ...

Gilead’s HIV drugs generated $20.8bn in full-year 2025 sales, up 6% from 2024. This was mainly fuelled by the company’s ...